This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Yes Virginia, There Is a Santa Claus Rally
by Mark Vickery
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
Company News for Dec 26, 2023
by Zacks Equity Research
Companies In The Articles: KRTX, BMY, NKE, TCEHY, RKLB
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
by Zacks Equity Research
Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.26, marking a +0.59% move from the previous day.
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
by Ekta Bagri
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
The Zacks Analyst Blog Highlights Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar
by Zacks Equity Research
Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar are included in this Analyst Blog.
Top Stock Reports for Microsoft, Booking Holdings & Bristol-Myers Squibb
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Booking Holdings Inc. (BKNG) and Bristol-Myers Squibb Company (BMY).
5 Stocks to Watch on Their Recent Dividend Hike
by Nalak Das
Five stocks that have recently raised dividends are: BMY, PWR, CARR, AVGO, OC.
Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.47, marking a -0.75% move from the previous day.
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
by Zacks Equity Research
Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $50.31 in the latest trading session, marking a +0.3% move from the prior day.
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
by Zacks Equity Research
Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
by Zacks Equity Research
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
by Zacks Equity Research
Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
by Zacks Equity Research
AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
by Zacks Equity Research
Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
by Zacks Equity Research
Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
by Zacks Equity Research
Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
by Ekta Bagri
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment
by Zacks Equity Research
Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.
Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback
by Zacks Equity Research
Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.
Company News for Nov 21, 2023
by Zacks Equity Research
Companies in The News Are: NVDA, BMY, PNM, ZM